- About CTTC
- Invention Disclosure
- News & Events
- Tech Connect
- CTTC MUSE - Blog
- Driving Innovation Forward Newsletter
- Past CTTC Events
Pharma Pipeline: Compounds, Core Capabilities, Collaboration
May 9 2013
Right now, at Vanderbilt University there are dozens of researchers studying small and large molecules and their effects on various diseases, searching for clues that will lead to the next big drug discovery. These researchers have already made ground-breaking discoveries in treating major brain disorders, obesity, cardiovascular disease, infectious diseases such as HIV and malaria, and various forms of cancer, to name a few. They have helped Vanderbilt achieve and maintain its position as a worldwide leader in pharmacological research. But what’s particularly exciting is what’s next.
Vanderbilt has divisions focused on neuroscience, cardiac and metabolic illness, oncology, infectious disease and a diverse range of therapeutics ranging from peptides, vaccines, and antibodies to small molecule drugs. Combined, these departments have approximately 85 therapeutics in the pharmaceutical pipeline -- either in development, seeking a partner, or partnered with industry. These compounds are the future of medicine. Some might become first-in-class therapeutics. Others might simply provide information that will lead to further investigation. Regardless, these 85 therapeutics are having and will continue to have an enormous impact on the scientific and medical world. They encourage exploration and collaboration. They push researchers to think outside of the box, to be creative. And they provide hope.